Surmodics Inc. (SU6)
XSTU 
Summary
SU6 Chart
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Surmodics Inc. Dividends
Surmodics Inc. Earnings
| 29 Jul 2025 (56 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
| 29 Jul 2025 (56 Days) Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
Surmodics Inc. (SU6) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Surmodics Inc. ever had a stock split?
Surmodics Inc. Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Gary R. Maharaj CEO | XSTU Exchange | US8688731004 ISIN |
| US Country | 389 Employees | - Last Dividend | 7 Dec 2000 Last Split | 4 Mar 1998 IPO Date |
Overview
Surmodics, Inc., along with its subsidiaries, is a pioneering company specializing in performance coating technologies for intravascular medical devices and the supply of crucial chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Its presence is not only strong in the United States but extends internationally, showcasing its global reach and influence in the medical and diagnostic fields. Since its inception in 1979, Surmodics has been headquartered in Eden Prairie, Minnesota, marking its long-standing contribution to the medical technology sector. The company operates through two primary segments: Medical Device and In Vitro Diagnostics (IVD), each focusing on distinct yet interrelated areas of expertise within the medical technology industry.
Products and Services
- Medical Device Segment
- In Vitro Diagnostics (IVD) Segment
This segment of Surmodics is dedicated to enhancing the performance of intravascular medical devices through surface modification coating technologies. These technologies aim to improve access, deliverability, and predictable deployment of various medical devices. Additionally, the segment specializes in drug-delivery coating technologies designed for site-specific drug delivery from the surface of a device, catering to several markets including neurovascular, peripheral, coronary, and structural heart. The manufacturing side of this segment produces vascular intervention medical devices like drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths, further demonstrating Surmodics' comprehensive approach to medical device innovation.
Surmodics' IVD segment concentrates on the development, manufacture, and sale of chemical and biological components essential for in vitro diagnostic immunoassay and molecular tests. This segment supports both diagnostic and biomedical research markets, offering a range of products including protein stabilizers, substrates, surface coatings, and antigens. Through its contributions, the IVD segment plays a critical role in advancing diagnostic capabilities and research efforts globally, highlighting Surmodics' commitment to improving health care through innovation.
Contact Information
